LongeVC is a venture capital firm focused on biotech and longevity investing, backing visionary founders advancing healthspan and lifespan innovations. The firm invests in early and mid-stage biotechnology and longevity-focused startups across Europe, the U.S., and Israel.
50% of their portfolio is in Biotech & Life Sciences. They made 4 investments in the last 12 months. Their most common stage is series-a (56% of deals). Average disclosed round size is $23.8M (across 13 rounds with reported amounts).
Portfolio
13
Fund Size
$120M
Top Stage
Series A
Last 12 Mo
4
Team
Ilya Suharenko
Managing Partner
Alex Zhavoronkov
Venture Partner
Artem Trotsyuk
Operating Partner - US
Evelyne Bischof
Venture Partner
Evgeny Izumchenko
Venture Partner
Greg Fishman
Venture Partner
Luis Angel
Venture Partner
Matt Kaeberlein
Venture Partner
Matthew Toner
Venture Partner
Michael Levitt
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Unnatural Products | Series A | $30M | Jul 2026 |
 Valink Therapeutics | Series A | $11.8M | Oct 2025 |
 Trogenix | Series A | — | Oct 2025 |
 Trogenix | Series A | $70M | Oct 2025 |
| Valink Therapeutics | Seed | $7.8M | Jan 2025 |
| Trogenix | Series A | $70M | Jan 2025 |
 Unnatural Products | Series A | $32M | Dec 2023 |
 Haut.AI | Seed | — | Nov 2023 |
 SiPhox | Series A | $17M | Jul 2023 |
 Siphox | Series A | $17M | Jan 2023 |
| SiPhox | Series A | $17M | Jan 2023 |
 Turn Biotechnologies | Unknown | — | Apr 2022 |
 Longenesis | Seed | $1.2M | Jun 2021 |
| AAOA | Seed | $17M | — |
| VValink | Seed | $11.8M | — |
 Proton Intelligence | Seed | $7.0M | — |
Top Co-Investors
Last updated: 7 October 2026